
    
      OBJECTIVES: I. Estimate the efficacy of suramin in patients with recurrent primary brain
      tumors as measured by radiographic response, time to progression, and survival. II. Assess
      the toxic effects of suramin in this patient population.

      OUTLINE: Single-Agent Chemotherapy. Suramin, SUR, NSC-34936.

      PROJECTED ACCRUAL: If at least 1 of the first 14 patients experiences at least a partial
      response, a total of 25 patients will be entered over approximately 30 months.
    
  